Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Si Sun,1 Lichen Tang,2 Jian Zhang,1 Fangfang Lv,1 Zhonghua Wang,1 Leiping Wang,1 Qunling Zhang,1 Chunlei Zheng,1 Lixin Qiu,1 Zhen Jia,1 Yunhua Lu,1 Guangyu Liu,2 Zhimin Shao,2 Biyun Wang,1 Xichun Hu1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, S...

Full description

Bibliographic Details
Main Authors:	Sun S, Tang L, Zhang J, Lv F, Wang Z, Wang L, Zhang Q, Zheng C, Qiu L, Jia Z, Lu Y, Liu G, Shao Z, Wang B, Hu X
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-03-01
Series:	International Journal of Nanomedicine
Online Access:	http://www.dovepress.com/cisplatin-improves-antitumor-activity-of-weekly-nab-paclitaxel-in-pati-a16165

Similar Items

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
by: Yannan Zhao, et al.
Published: (2018-10-01)

The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer
by: M A Frolova
Published: (2016-09-01)

A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer
by: Haili Lu, et al.
Published: (2021-07-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial
by: Wang D, et al.
Published: (2018-09-01)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
by: De Luca R, et al.
Published: (2018-06-01)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
by: Junji Tsurutani, et al.
Published: (2021-02-01)

Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
by: Xi Guo, MD, et al.
Published: (2020-03-01)

Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life
by: De Luca R, et al.
Published: (2019-02-01)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
by: Vera eHirsh, et al.
Published: (2014-07-01)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
by: Lazzaro C, et al.
Published: (2013-04-01)

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer
by: Huang L, et al.
Published: (2015-03-01)

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
by: Ruihua Xu, et al.
Published: (2017-12-01)

Nab-paclitaxel monotherapy in patients with metastatic breast cancer with visceral crisis: evaluation of efficacy and tolerability in clinical practice
by: L. Yu. Vladimirova, et al.
Published: (2019-06-01)

The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case.
by: L. G. Zhukova, et al.
Published: (2018-07-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
by: Frontiers in Oncology Editorial Office
Published: (2014-10-01)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
by: Julia Foldi, et al.
Published: (2021-02-01)

Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination
by: Putao Cen, et al.
Published: (2019-07-01)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020-05-01)

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis
by: Mahtani RL, et al.
Published: (2018-02-01)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
by: Dranitsaris G, et al.
Published: (2015-05-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
by: Prakash Vishnu, et al.
Published: (2011-04-01)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
by: Iwase H, et al.
Published: (2011-07-01)

Excellent Biochemical Response to Polychemotherapy with Nab-Paclitaxel/Gemcitabine in an 82-Year-Old Female with Metastatic Breast Cancer
by: Siegfried J. Völkl
Published: (2014-09-01)

nab-Paclitaxel for the treatment of pancreatic cancer
by: Kim G
Published: (2017-03-01)

A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
by: Yoshihiro Hattori, et al.
Published: (2020-02-01)

Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer
by: Zhu X, et al.
Published: (2018-10-01)

Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
by: Wang HY, et al.
Published: (2016-09-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
by: Tomoyuki Araya, et al.
Published: (2020-12-01)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
by: Huang L, et al.
Published: (2017-12-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
by: Kunihiko Funaishi, et al.
Published: (2017-06-01)

Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
by: Daniela Bianconi, et al.
Published: (2017-07-01)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
by: Ilario Giovanni Rapposelli, et al.
Published: (2021-05-01)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
by: Alberto Montero, et al.
Published: (2012-12-01)

Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer
by: Liu B, et al.
Published: (2017-01-01)

Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience
by: E. I. Borisova, et al.
Published: (2018-11-01)

Synergy of Nab-paclitaxel and Bevacizumab in Eradicating Large Orthotopic Breast Tumors and Preexisting Metastases
by: Lisa D. Volk, et al.
Published: (2011-04-01)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
by: Al-Hajeili M, et al.
Published: (2014-02-01)

The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids
by: Xiao X, et al.
Published: (2020-06-01)